ophthalmologytimes9d
SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...
Joplin Globe16d
MediPrint Ophthalmics Presents Promising Results from Phase 2b Clinical Trial of LL-BMT1 for Glaucoma at American Academy of Optometry
MediPrint® Ophthalmics (MediPrint), a clinical-stage ophthalmic drug delivery company based in San Diego, announced the results of the Company’s Phase 2b clinical trial of LL-BMT1. Employing a novel ...
Medindia20d
Bimatoprost - Indications, Dosage, Side Effects and Precautions
Get detailed information on Bimatoprost, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension
SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative ...
Medscape8y
Effect of Switching From Latanoprost to Bimatoprost in POAG
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...